{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:27:41Z","timestamp":1761895661543,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"\u201cSandro Pitigliani\u201d Foundation"},{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.breast.2013.04.019","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T18:25:44Z","timestamp":1369247144000},"page":"926-932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients"],"prefix":"10.1016","volume":"22","author":[{"given":"G.","family":"Sanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pestrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Zafarana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cavaciocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.04.019_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"issue":"Suppl. 12","key":"10.1016\/j.breast.2013.04.019_bib2","doi-asserted-by":"crossref","first-page":"xii2","DOI":"10.1093\/annonc\/mdm532","article-title":"Adjuvant chemotherapy\u2013yes or no? Prognostic markers in early breast cancer","volume":"18","author":"Piccart-Gebhart","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib3","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMe068204","article-title":"Adjuvant chemotherapy for breast cancer\u201330 years later","volume":"355","author":"Levine","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.04.019_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CBC.2006.n.013","article-title":"Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg","volume":"7","author":"Dang","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2013.04.019_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/jnci\/96.20.1492","article-title":"The Gompertzian view: Norton honored for role in establishing cancer treatment approach","volume":"96","author":"Schmidt","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"Suppl. 3","key":"10.1016\/j.breast.2013.04.019_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","article-title":"Theoretical concepts and the emerging role of taxanes in adjuvant therapy","volume":"6","author":"Norton","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2013.04.019_bib8","first-page":"7067","article-title":"A\u00a0Gompertzian model of human breast cancer growth","volume":"48","author":"Norton","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.04.019_bib9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib10","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"22","author":"Martin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.04.019_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1470-2045(04)01494-9","article-title":"Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer","volume":"5","author":"Nowak","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib12","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.04.019_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/annonc\/mdm539","article-title":"Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10\/00","volume":"19","author":"Fountzilas","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10549-011-1913-4","article-title":"Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10\/00 phase III trial","volume":"132","author":"Gogas","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.04.019_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1999.17.1.93","article-title":"Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy","volume":"17","author":"Hudis","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib17","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","article-title":"Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study","volume":"28","author":"Moebus","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1008345432342","article-title":"A\u00a0feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer","volume":"11","author":"Di Leo","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/bjc.2011.414","article-title":"High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer","volume":"105","author":"Brain","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2013.04.019_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/mdl355","volume":"18","author":"Piedbois","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib21","article-title":"NSABP B-38: definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC\u00a0\u2192\u00a0paclitaxel (P) plus gemcitabine (G) with DD AC\u00a0\u2192\u00a0P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer","volume":"30","author":"Swain","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/COC.0b013e3181bead47","article-title":"Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer","volume":"33","author":"Jacot","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2013.04.019_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3816\/CBC.2008.n.027","article-title":"A\u00a0phase II feasibility trial of dose-dense docetaxel followed by doxorubicin\/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer","volume":"8","author":"Yardley","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2013.04.019_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3816\/CBC.2007.n.029","article-title":"Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study","volume":"7","author":"Lambert-Falls","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2013.04.019_bib25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1200\/JCO.2007.14.3941","article-title":"Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer","volume":"26","author":"Puhalla","year":"2008","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613001008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613001008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:33:26Z","timestamp":1760776406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0960977613001008"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.04.019","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}